These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12941111)

  • 21. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
    Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
    J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    Ann Intern Med; 2004 Jun; 140(11):867-73. PubMed ID: 15172900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
    Lachish T; Rudensky B; Slotki I; Zevin S
    Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
    Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
    Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalidomide-induced remission of lichen planopilaris.
    Boyd AS; King LE
    J Am Acad Dermatol; 2002 Dec; 47(6):967-8. PubMed ID: 12451391
    [No Abstract]   [Full Text] [Related]  

  • 28. Persistent generalized lichen nitidus successfully treated with enoxaparin sodium.
    Cholongitas E; Kokolakis G; Giannikaki E; Ioannidou D
    Am J Clin Dermatol; 2008; 9(5):349-50. PubMed ID: 18717613
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC; Wang J; Song Y; Pursley J; Wastall P; Wright R; Lacreta F; Frost C
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lichen planus in the child: 25 cases. Clinical, follow-up and therapeutic aspects].
    Rybojad M; Moraillon I; Cordoliani F; Akerman C; Ducloy G; Prigent F; Vignon MD; Morel P
    Ann Dermatol Venereol; 2000; 127(6-7):661. PubMed ID: 11041823
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
    Ann Intern Med; 2004 Jun; 140(11):I44. PubMed ID: 15172926
    [No Abstract]   [Full Text] [Related]  

  • 34. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
    Friedrich E; Hameed AB
    J Perinatol; 2010 Apr; 30(4):253-7. PubMed ID: 19829297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE.
    Lassen MR; Fisher W; Mouret P; Agnelli G; George D; Kakkar A; Mismetti P; Turpie AG;
    J Thromb Haemost; 2012 May; 10(5):822-32. PubMed ID: 22429800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of subcutaneous enoxaparin as ancillary therapy in STEMI patients receiving fibrinolysis.
    Rott D; Leibowitz D
    Int J Cardiol; 2013 Sep; 168(2):1582. PubMed ID: 23398828
    [No Abstract]   [Full Text] [Related]  

  • 37. Fondaparinux versus enoxaparin for prevention of venous thromboembolism.
    Borja J; Olivella P; Curto J
    Lancet; 2002 Nov; 360(9345):1603-4; author reply 1605. PubMed ID: 12443626
    [No Abstract]   [Full Text] [Related]  

  • 38. Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
    Hebbeler SL; Marciniak CM; Crandall S; Chen D; Nussbaum S; Mendelewski S
    J Spinal Cord Med; 2004; 27(3):236-40. PubMed ID: 15478526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fondaparinux versus enoxaparin for prevention of venous.
    Thaler H; Sim E
    Lancet; 2002 Nov; 360(9345):1604; author reply 1605. PubMed ID: 12443627
    [No Abstract]   [Full Text] [Related]  

  • 40. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.